• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Tarsa Therapeutics

edit

Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.

Recent Milestones

edit

• 
  Tarsa Therapeutics received $28M in Series B funding. (3/16/12)
  Posted 3/16/12 at 5:50am via prnewswire.com
• 
  Tarsa Therapeutics received $24.5M in Venture Round funding. (7/12/11)
  Posted 7/12/11 at 4:32pm via fiercebiotech.com
• 
  Tarsa Therapeutics received $24M in Series A funding. (1/17/10)
  Posted 1/19/10 at 11:35pm via onbiovc.com
• 
  Tarsa Therapeutics added David Brand as President, Founder & Chief Executive Officer, Director.
  Posted 3/16/12 at 5:44am
• 
  Tarsa Therapeutics added James Gilligan as Founder & Chief Scientific Officer.
  Posted 3/16/12 at 5:44am

Videos

Screenshots

edit

Above: Tarsa Therapeutics
Uploaded: 3/16/12

Sources

1. Tarsa Therapeutics, Inc.: Series A $24M (onbiovc.com) [edit]
2. Tarsa Therapeutics adds to $24.5M financing, advances osteoporosis drug (fiercebiotech.com) [edit]
3. Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin (prnewswire.com) [edit]